Cologne, Germany, January 22, 2015 / B3C newswire / - New Oncology and the University Hospital Oslo announced today that they have entered into a collaboration to identify alterations in cancer-related tumour genes that predict a patient’s response or resistance to targeted therapies.
Under this agreement, New Oncology will apply its proprietary diagnostic platform ‘NEO’ that provides a fully informative molecular cancer profile from the smallest quantities of patient samples with short turn-around times. No financial details were disclosed.
“Dramatic responses to targeted therapies in patients with advanced solid tumours bearing drug-sensitizing mutations have shifted the paradigm of cancer treatment towards a comprehensive molecular characterization before initiation of treatment. The growing number of targeted drugs, different types of targetable genome alterations and the occurrence of resistance mechanisms are increasing challenges for clinical diagnostics. Technological and computational advances in the field of tumour diagnostics finally put us in the position to perform comprehensive, sensitive and fast analysis of all different types of genome alterations on routine tumour specimens. This is a pivotal step in matching the right patients with the right drugs, providing broad access to personalized cancer medicine to all patients” commented Prof. Roman Thomas, founder of New Oncology.
About New Oncology
New Oncology’s proprietary diagnostic platform ‘NEO’ empowers physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. Our pan-cancer diagnostic test NEOplus reliably detects actionable genetic alterations with short turn-around times. In contrast to conventional testing, NEOplus identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as novel and known translocations, from one single patient sample. We work with a tumour board comprising renowned cancer experts, facilitating translation of the latest targeted therapy findings into optimized patient care.
Contact
Dr. Jutta Fritz
NEO New Oncology AG / Blackfield AG
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.